Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen

Vaccine

Volumn 28, Issue 43, 2010, Pages 7070-7080

  Jain, Sumiti ^a   Patrick, Amy J ^a   Rosenthal, Kenneth L ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

HIV 1; Membrane proximal external region (MPER) epitopes; Mucosal antibodies; Vaccine; Virus like particles

Indexed keywords

ASPARAGINYLTRYPTOPHANYLPHENYLALANYLASPARTYLISOLEUCYLTHREONINE; EPITOPE; GAG PROTEIN; GLUTAMYLLEUCYLASPARTYLLYSYLTRYPTOPHANYLALANINE; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MEMBRANE PROXIMAL EXTERNAL REGION EPITOPE; PROTEIN P55; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CPG ISLAND; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS LIKE AGENT;

ADENOVIRIDAE; ADMINISTRATION, INTRANASAL; AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; CPG ISLANDS; EPITOPES; FEMALE; GENETIC VECTORS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED C57BL; NEUTRALIZATION TESTS; TANDEM REPEAT SEQUENCES; VACCINES, DNA; VACCINES, VIRUS-LIKE PARTICLE;

EID: 77957336593     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.009     Document Type: Article

References (71)

1. Haase A.T. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010, 464(7286):217-223.
2. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005, 191(5):654-665.
3. Lee D., Graham B.S., Chiu Y.L., Gilbert P.B., McElrath M.J., Belshe R.B., et al. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis 2004, 190(5):903-907.
4. Pancera M., Majeed S., Ban Y.E., Chen L., Huang C.C., Kong L., et al. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci USA 2010, 107(3):1166-1171.
5. Gray E.S., Moore P.L., Pantophlet R.A., Morris L. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. J Virol 2007, 81(19):10769-10776.
6. Chen L., Kwon Y.D., Zhou T., Wu X., O'Dell S., Cavacini L., et al. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 2009, 326(5956):1123-1127.
7. Nandi A., Lavine C.L., Wang P., Lipchina I., Goepfert P.A., Shaw G.M., et al. Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology 2010, 396(2):339-348.
8. Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001, 17(18):1757-1765.
9. Mehandru S., Wrin T., Galovich J., Stiegler G., Vcelar B., Hurley A., et al. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J Virol 2004, 78(24):14039-14042.
10. Crooks E.T., Moore P.L., Richman D., Robinson J., Crooks J.A., Franti M., et al. Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Hum Antibodies 2005, 14(3-4):101-113.
11. Hofmann-Lehmann R., Vlasak J., Rasmussen R.A., Smith B.A., Baba T.W., Liska V., et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol 2001, 75(16):7470-7480.
12. Xu W., Hofmann-Lehmann R., McClure H.M., Ruprecht R.M. Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV. Vaccine 2002, 20(15):1956-1960.
13. de Rosny E., Vassell R., Jiang S., Kunert R., Weiss C.D. Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J Virol 2004, 78(5):2627-2631.
14. Golding H., Zaitseva M., de Rosny E., King L.R., Manischewitz J., Sidorov I., et al. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J Virol 2002, 76(13):6780-6790.
15. Parker C.E., Deterding L.J., Hager-Braun C., Binley J.M., Schulke N., Katinger H., et al. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J Virol 2001, 75(22):10906-10911.
16. Kunert R., Wolbank S., Stiegler G., Weik R., Katinger H. Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res Hum Retroviruses 2004, 20(7):755-762.
17. Gissmann L. HPV vaccines: preclinical development. Arch Med Res 2009, 40(6):466-470.
18. Vietheer P.T., Boo I., Drummer H.E., Netter H.J. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies. Antivir Ther 2007, 12(4):477-487.
19. Deml L., Speth C., Dierich M.P., Wolf H., Wagner R. Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol 2005, 42(2):259-277.
20. Tsunetsugu-Yokota Y., Morikawa Y., Isogai M., Kawana-Tachikawa A., Odawara T., Nakamura T., et al. Yeast-derived human immunodeficiency virus type 1 p55(gag) virus-like particles activate dendritic cells (DCs) and induce perforin expression in Gag-specific CD8(+) T cells by cross-presentation of DCs. J Virol 2003, 77(19):10250-10259.
21. Wong S.B., Siliciano R.F. Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in mice. J Virol 2005, 79(3):1701-1712.
22. Yao Q., Bu Z., Vzorov A., Yang C., Compans R.W. Virus-like particle and DNA-based candidate AIDS vaccines. Vaccine 2003, 21(7-8):638-643.
23. Paliard X., Liu Y., Wagner R., Wolf H., Baenziger J., Walker C.M. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res Hum Retroviruses 2000, 16(3):273-282.
24. Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., Pavlakis G.N., Xiang Z.Q., Wlazlo A.P., et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 2003, 170(3):1416-1422.
25. Wagner R., Deml L., Schirmbeck R., Niedrig M., Reimann J., Wolf H. Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles. Virology 1996, 220(1):128-140.
26. Chege G.K., Shephard E.G., Meyers A., van Harmelen J., Williamson C., Lynch A., et al. HIV-1 subtype C Pr55gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine. J Gen Virol 2008, 89(Pt 9):2214-2227.
27. Notka F., Stahl-Hennig C., Dittmer U., Wolf H., Wagner R. Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies. Vaccine 1999, 18(3-4):291-301.
28. Kang C.Y., Luo L., Wainberg M.A., Li Y. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Biol Chem 1999, 380(3):353-364.
29. Zheng B., Graham F.L., Johnson D.C., Hanke T., McDermott M.R., Prevec L. Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors. Vaccine 1993, 11(12):1191-1198.
30. Zolla-Pazner S., Cohen S.S., Krachmarov C., Wang S., Pinter A., Lu S. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology 2008, 372(2):233-246.
31. Moseri A., Tantry S., Sagi Y., Arshava B., Naider F., Anglister J. An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120. Virology 2010.
32. Stamatatos L., Morris L., Burton D.R., Mascola J.R. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat Med 2009, 15(8):866-870.
33. Moore P.L., Crooks E.T., Porter L., Zhu P., Cayanan C.S., Grise H., et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 2006, 80(5):2515-2528.
34. Ng P., Parks R.J., Cummings D.T., Evelegh C.M., Graham F.L. An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method. Hum Gene Ther 2000, 11(5):693-699.
35. Ng P., Parks R.J., Cummings D.T., Evelegh C.M., Sankar U., Graham F.L. A high-efficiency Cre/loxP-based system for construction of adenoviral vectors. Hum Gene Ther 1999, 10(16):2667-2672.
36. Kwant A., Rosenthal K.L. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2. Vaccine 2004, 22(23-24):3098-3104.
37. Jiang J.Q., Patrick A., Moss R.B., Rosenthal K.L. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides. J Virol 2005, 79(1):393-400.
38. Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol 2005, [Chapter 12: p. Unit 12 11].
39. Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol 2009, 21(3):346-351.
40. Marshall W.G., Boone B.A., Burgos J.D., Gografe S.I., Baldwin M.K., Danielson M.L., et al. Electroporation-mediated delivery of a naked DNA plasmid expressing VEGF to the porcine heart enhances protein expression. Gene Ther 2010, 17(3):419-423.
41. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374(6522):546-549.
42. Tighe H., Takabayashi K., Schwartz D., Marsden R., Beck L., Corbeil J., et al. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol 2000, 30(7):1939-1947.
43. Hartmann G., Krieg A.M. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 2000, 164(2):944-953.
44. Gursel M., Verthelyi D., Gursel I., Ishii K.J., Klinman D.M. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol 2002, 71(5):813-820.
45. Askew D., Chu R.S., Krieg A.M., Harding C.V. CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. J Immunol 2000, 165(12):6889-6895.
46. Shen R., Drelichman E.R., Bimczok D., Ochsenbauer C., Kappes J.C., Cannon J.A., et al. GP41-specific antibody blocks cell-free HIV type 1 transcytosis through human rectal mucosa and model colonic epithelium. J Immunol 2010, 184(7):3648-3655.
47. Devito C., Broliden K., Kaul R., Svensson L., Johansen K., Kiama P., et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 2000, 165(9):5170-5176.
48. Alfsen A., Iniguez P., Bouguyon E., Bomsel M. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J Immunol 2001, 166(10):6257-6265.
49. Matoba N., Griffin T.A., Mittman M., Doran J.D., Alfsen A., Montefiori D.C., et al. Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes. Curr HIV Res 2008, 6(3):218-229.
50. Phogat S., Svehla K., Tang M., Spadaccini A., Muller J., Mascola J., et al. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles. Virology 2008, 373(1):72-84.
51. Lapelosa M., Gallicchio E., Arnold G.F., Arnold E., Levy R.M. In silico vaccine design based on molecular simulations of rhinovirus chimeras presenting HIV-1 gp41 epitopes. J Mol Biol 2009, 385(2):675-691.
52. Matoba N., Geyer B.C., Kilbourne J., Alfsen A., Bomsel M., Mor T.S. Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate. Vaccine 2006, 24(23):5047-5055.
53. Arnold G.F., Velasco P.K., Holmes A.K., Wrin T., Geisler S.C., Phung P., et al. Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J Virol 2009, 83(10):5087-5100.
54. Hinz A., Schoehn G., Quendler H., Hulsik D.L., Stiegler G., Katinger H., et al. Characterization of a trimeric MPER containing HIV-1 gp41 antigen. Virology 2009, 390(2):221-227.
55. Bryson S., Julien J.P., Hynes R.C., Pai E.F. Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications. J Virol 2009, 83(22):11862-11875.
56. Zwick M.B., Jensen R., Church S., Wang M., Stiegler G., Kunert R., et al. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 2005, 79(2):1252-1261.
57. Haynes B.F., Fleming J., St Clair E.W., Katinger H., Stiegler G., Kunert R., et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308(5730):1906-1908.
58. Haynes B.F., Moody M.A., Verkoczy L., Kelsoe G., Alam S.M. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum Antibodies 2005, 14(3-4):59-67.
59. Li Y., Svehla K., Louder M.K., Wycuff D., Phogat S., Tang M., et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 2009, 83(2):1045-1059.
60. Binley J.M., Lybarger E.A., Crooks E.T., Seaman M.S., Gray E., Davis K.L., et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 2008, 82(23):11651-11668.
61. Alam S.M., Morelli M., Dennison S.M., Liao H.X., Zhang R., Xia S.M., et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci USA 2009, 106(48):20234-20239.
62. Simek M.D., Rida W., Priddy F.H., Pung P., Carrow E., Laufer D.S., et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 2009, 83(14):7337-7348.
63. Nakahara T., Nomura W., Ohba K., Ohya A., Tanaka T., Hashimoto C., et al. Remodeling of dynamic structures of HIV-1 envelope proteins leads to synthetic antigen molecules inducing neutralizing antibodies. Bioconjug Chem 2010.
64. Gorny M.K., Stamatatos L., Volsky B., Revesz K., Williams C., Wang X.H., et al. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol 2005, 79(8):5232-5237.
65. Joyce J.G., Krauss I.J., Song H.C., Opalka D.W., Grimm K.M., Nahas D.D., et al. An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions. Proc Natl Acad Sci USA 2008, 105(41):15684-15689.
66. Dey B., Svehla K., Xu L., Wycuff D., Zhou T., Voss G., et al. Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog 2009, 5(5):pe1000445.
67. Reimer U. Prediction of linear B-cell epitopes. Methods Mol Biol 2009, 524:335-344.
68. Bui H.H., Peters B., Assarsson E., Mbawuike I., Sette A. Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc Natl Acad Sci USA 2007, 104(1):246-251.
69. Deml L., Kratochwil G., Osterrieder N., Knuchel R., Wolf H., Wagner R. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain. Virology 1997, 235(1):10-25.
70. Gonzalez M.C., Kostrzak A., Guetard D., Pniewski T., Sala M. HIV-1 derived peptides fused to HBsAg affect its immunogenicity. Virus Res 2009, 146(1-2):107-114.
71. Ludwig C., Wagner R. Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol 2007, 18(6):537-545.